Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8TD30

UPID:
ALAT2_HUMAN

ALTERNATIVE NAMES:
Glutamate pyruvate transaminase 2; Glutamic--alanine transaminase 2; Glutamic--pyruvic transaminase 2

ALTERNATIVE UPACC:
Q8TD30; Q8N9E2

BACKGROUND:
Alanine aminotransferase 2, known for its alternative names such as Glutamic--alanine transaminase 2, is integral to the conversion of alanine and 2-oxoglutarate into pyruvate and glutamate, respectively. This enzymatic process is essential for the balance of nitrogen and glucose metabolism in the body.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in amino acid metabolism and its link to Neurodevelopmental disorder with spastic paraplegia and microcephaly, Alanine aminotransferase 2 represents a significant target for drug discovery. Exploring its mechanisms could lead to innovative treatments for this autosomal recessive syndrome, offering hope for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.